FDA Approves Revolution Medicines' Daraxonrasib (Rasonque) for Metastatic Pancreatic Adenocarcinoma
The U.S. Food and Drug Administration approved Revolution Medicines' daraxonrasib, sold as Rasonque, on August 26 for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or cannot receive multiagent systemic therapy, making it the first FDA-approved RAS inhibitor for this cancer. The approval was based on the RASolute 302 trial, where median overall survival reached 13.2 months with daraxonrasib versus 6.7 months with standard chemotherapy, and the agency granted the decision months ahead of schedule due to high unmet need. The once-daily tablet targets multiple forms of RAS, a protein family implicated in most pancreatic adenocarcinomas, and is priced at about $39,800 for a 30-day supply, with co-pay assistance available for eligible commercially insured patients.
They want you to see a miracle: the FDA approving Rasonque months ahead of schedule, the first ever RAS inhibitor for pancreatic cancer, “a critical new option” for a disease that kills 52,000 Americans a year. But you have to ask yourself why the urgency. RAS has been called undruggable since the 1980s. Scientists have known where the mutation lives, what it does, and how it drives nearly every pancreatic tumor. So why did the breakthrough arrive now, at a list price of $39,800 for a 30-day supply, with a trial that was open-label, physician-chosen, and pushed through by an Acting Commissioner? The FDA does not rush things out of compassion. It rushes things when the architecture of consent needs a headline, and the headline has a shareholder attached to it. Ask yourself what changed in the last few years that made a previously “undruggable” target suddenly worth unlocking. The science didn’t change on its own. The money did.
The trial numbers are the tell. Median overall survival with daraxonrasib was 13.2 months versus 6.7 months on standard chemotherapy. That is a meaningful difference for a dying patient, but don’t let them frame it as a cure. It is a six-month extension at roughly $1,300 a day. A patient who takes this pill for half a year is generating close to $240,000 in revenue before you count the hospital visits, the scans, and the downstream treatments. Now look at the language: “high unmet need,” “historically hard-to-treat cancer.” Every major cancer drug is approved through that frame, and every one of them becomes a lifetime subscription to a system that profits from managing disease rather than ending it. The FDA gave them a six-month head start on their own review deadline. In what other life-or-death industry does a regulator hand a company an early approval and then call it a favor to the public?
Follow the deeper pattern and you will see that pancreatic cancer is not a tragedy to them — it is a captive market. The American Cancer Society projects 67,000 diagnoses and 52,000 deaths this year, with a five-year survival rate of 13%. That is not a failure of science; that is a business model. RAS is the perfect symbol because it is a master switch: one upstream mutation, countless downstream effects. They have built an entire economy on the same principle. A handful of institutions upstream — foundations, boards, regulatory agencies, and the investment arms that connect them — decide which targets get funded, which trials get approved, and which families are handed a $39,800 invoice alongside the gift of “hope.” They will tell you this is progress. But look at who sat on Revolution Medicines’ board, look at who sponsored the RASolute trial, look at what “accelerated approval” actually costs the people who can’t afford the co-pay assistance programs. Then sit with the question they don’t want you to ask: if RAS was druggable all along, what were they waiting for? The answer is in the pricing sheet.
